Innovita Biological Technology688253.SHValuation Analysis

As of Oct 19, 2026, Innovita Biological Technology (688253.SH) trades at a P/E of 130.00x, P/B of 3.24x, P/S of 23.30x, and a dividend yield of 0.92%.
Longitudinal percentile comparison: P/E sits at the 94th percentile over the trailing 10Y window (vs. 92nd percentile over 3Y); P/B sits at the 82nd percentile over the trailing 10Y window (vs. 80th percentile over 3Y); P/S sits at the 94th percentile over the trailing 10Y window (vs. 92nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 86th percentile within its industry and the 86th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.35%, ranking at the 68th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 12.5 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 1.35% total shareholder yield, 0.92% is paid out as dividends and roughly 0.43% is implied to come from buybacks — both channels are meaningfully in play. Innovita Biological Technology operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.